HLA Tissue Typing Class I & Class II (Patient) at Chughtai Lab

HLA Tissue Typing Class I & Class II (Patient) at Chughtai Lab

Human Leukocyte Antigen (HLA) Tissue Typing Class I & Class II (Patient) is a highly specialized molecular diagnostic test performed to determine the unique genetic profile of an individual’s immune system. The HLA system, also known as the Major Histocompatibility Complex (MHC) in humans, is a cluster of genes located on the short arm of chromosome 6. These genes encode cell-surface proteins that play a fundamental role in the immune system’s ability to distinguish between self and non-self molecules. At Chughtai Lab, Pakistan’s premier diagnostic network, this test is executed using state-of-the-art molecular biology techniques to provide highly accurate and clinically actionable results for patients undergoing organ transplantation, bone marrow transplantation, or diagnostic evaluations for specific autoimmune diseases and drug hypersensitivities.

The HLA system is divided into two primary classes that are evaluated in this comprehensive panel: Class I and Class II. HLA Class I molecules include HLA-A, HLA-B, and HLA-C, which are expressed on the surface of almost all nucleated cells in the human body. These molecules present endogenous peptides (derived from within the cell, such as viral or tumor proteins) to CD8+ cytotoxic T-lymphocytes. HLA Class II molecules, which include HLA-DR, HLA-DQ, and HLA-DP, are primarily expressed on professional antigen-presenting cells such as dendritic cells, macrophages, and B-lymphocytes. These molecules present exogenous peptides (derived from extracellular pathogens) to CD4+ helper T-lymphocytes. Understanding the precise alleles present at these loci is critical for matching donors and recipients in transplantation, as mismatching can trigger a profound and potentially catastrophic immune response.

The diagnostic value of HLA Tissue Typing Class I & Class II (Patient) at Chughtai Lab cannot be overstated. By utilizing advanced Polymerase Chain Reaction (PCR) methodologies, such as Sequence-Specific Oligonucleotide Probing (SSOP) or Next-Generation Sequencing (NGS), Chughtai Lab provides high-resolution typing that identifies specific nucleotide sequences of the HLA alleles. This level of precision is essential for modern transplant medicine, where even single amino acid mismatches can influence graft survival, the development of donor-specific antibodies (DSA), and the occurrence of Graft-Versus-Host Disease (GVHD). Furthermore, this test serves as a vital diagnostic aid for identifying genetic predispositions to various autoimmune disorders and predicting severe adverse drug reactions, thereby enabling personalized and preventive clinical management.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the integrity of the specimen and the accuracy of the molecular testing process. Patients undergoing HLA Tissue Typing Class I & Class II (Patient) at Chughtai Lab should observe the following guidelines:

• No Fasting Required: There is no requirement for fasting before this test. Patients may eat and drink normally prior to sample collection.
• Medication History: Inform the healthcare provider and the laboratory staff of all current medications, especially immunosuppressants, chemotherapy agents, or corticosteroids. While these medications do not typically alter the genetic DNA sequence, they are important for overall clinical correlation.
• Transfusion History: It is critical to inform the laboratory if the patient has received a blood transfusion or a bone marrow transplant recently. Recent blood transfusions can introduce donor white blood cells into the patient’s circulation, potentially interfering with molecular typing results. In such cases, specific protocols or waiting periods may be advised.
• Hydration: Staying well-hydrated is recommended as it facilitates easier venipuncture and ensures a smooth sample collection process.
• Identification and Documentation: Ensure that all clinical referral forms, transplant documentation, and official identification are complete and presented at the time of registration at Chughtai Lab.

During the Procedure

The collection of the sample for HLA Tissue Typing Class I & Class II (Patient) is a routine venipuncture procedure performed by highly trained phlebotomists at Chughtai Lab. The process is designed to maximize patient comfort and ensure sample sterility:

• Patient Positioning: The patient is comfortably seated, and the arm is positioned on a stable support.
• Site Selection and Sanitization: The phlebotomist identifies a suitable vein, typically in the antecubital fossa (inner elbow), and cleanses the area thoroughly with an antiseptic solution (such as 70% isopropyl alcohol) to prevent contamination.
• Sample Collection: A sterile, single-use needle is inserted into the vein, and approximately 5 to 10 mL of whole blood is collected into specialized tubes containing ethylenediaminetetraacetic acid (EDTA) or Acid Citrate Dextrose (ACD) as anticoagulants. These preservatives are essential for maintaining the stability of genomic DNA.
• Post-Collection Care: Once the blood is drawn, the needle is gently removed, and pressure is applied to the puncture site with a sterile cotton ball or gauze to prevent hematoma formation. A small bandage is then applied.
• Duration and Experience: The entire venipuncture process takes less than five minutes. Patients may feel a brief, mild pinch as the needle enters the vein, but the procedure is generally painless.
• Safety and Quality Control: Chughtai Lab adheres to strict barcoding and labeling protocols at the bedside to eliminate any risk of sample misidentification. The sample is immediately prepared for transport to the molecular pathology department under controlled temperature conditions.

When is a HLA Tissue Typing Class I & Class II (Patient) Performed?

Renal and Solid Organ Transplantation

HLA Tissue Typing Class I & Class II (Patient) is a mandatory pre-requisite for patients undergoing renal (kidney), hepatic (liver), or cardiac (heart) transplantation. In solid organ transplantation, matching the HLA antigens of the recipient (patient) with those of the potential donor is critical to minimize the risk of allorecognition. When a recipient’s immune system recognizes the donor’s HLA molecules as foreign, it initiates an immune response that can lead to hyperacute, acute, or chronic graft rejection. Performing high-resolution HLA typing allows transplant surgeons and nephrologists to assess the immunological risk, calculate the virtual crossmatch, and design appropriate post-transplant immunosuppressive regimens to ensure long-term graft survival.

Hematopoietic Stem Cell Transplantation (HSCT)

For patients suffering from hematological malignancies (such as leukemia, lymphoma, or myeloma) or non-malignant hematological disorders (such as aplastic anemia or thalassemia major), hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation is often the only curative option. In HSCT, HLA matching is even more stringent than in solid organ transplants. A high-resolution match of Class I (HLA-A, -B, -C) and Class II (HLA-DRB1, -DQB1) loci—often referred to as a 10/10 match—is required. Mismatches in these loci can lead to Graft-Versus-Host Disease (GVHD), a life-threatening condition where the donor’s immune cells attack the recipient’s healthy tissues, or graft failure, where the recipient’s residual immune system rejects the donor stem cells.

Autoimmune Disease Association and Diagnosis

Certain HLA alleles are strongly associated with an increased susceptibility to specific autoimmune and inflammatory disorders. Physicians request HLA Tissue Typing Class I & Class II (Patient) when clinical symptoms suggest an autoimmune etiology but standard diagnostic criteria are inconclusive. For example, the presence of the HLA-B27 allele is highly correlated with Ankylosing Spondylitis and other seronegative spondyloarthropathies. Similarly, HLA-DR4 is associated with Rheumatoid Arthritis, while HLA-DQ2 and HLA-DQ8 are present in over 95% of patients with Celiac Disease. Identifying these genetic markers helps clinicians confirm diagnoses, estimate prognosis, and initiate targeted therapeutic interventions early in the disease course.

Drug Hypersensitivity Screening

Modern medicine increasingly utilizes pharmacogenomics to prevent severe, life-threatening adverse drug reactions. HLA Tissue Typing Class I & Class II (Patient) is performed to screen patients before prescribing specific medications known to trigger severe hypersensitivity syndromes, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). For instance, screening for the HLA-B*57:01 allele is mandatory before initiating Abacavir therapy in HIV patients, as individuals carrying this allele have a near 100% risk of developing a severe systemic hypersensitivity reaction. Similarly, testing for HLA-B*15:02 is recommended before prescribing Carbamazepine, particularly in populations of Asian descent, to prevent catastrophic cutaneous drug reactions.

Platelet Transfusion Refractoriness Management

Patients who receive multiple platelet transfusions, such as those undergoing intensive chemotherapy or bone marrow transplantation, may develop HLA antibodies that rapidly destroy transfused platelets. This clinical state, known as platelet transfusion refractoriness, prevents the patient’s platelet count from rising adequately after transfusion, leaving them at high risk for severe bleeding. HLA Tissue Typing Class I & Class II (Patient) is performed to identify the patient’s HLA profile, allowing blood banks to select HLA-matched or HLA-compatible platelet donors. This ensures that the transfused platelets survive in the patient’s circulation and effectively manage or prevent hemorrhagic complications.

What Does a HLA Tissue Typing Class I & Class II (Patient) Detect?

The HLA Tissue Typing Class I & Class II (Patient) test at Chughtai Lab is designed to detect and identify specific alleles at multiple highly polymorphic loci within the human genome. The molecular analysis provides a detailed profile of the following genetic markers:

• HLA-A Alleles: Detects specific Class I alleles (e.g., HLA-A*02, HLA-A*24) that are critical for solid organ and stem cell transplant matching.
• HLA-B Alleles: Identifies Class I variants associated with transplantation compatibility and numerous disease associations.
• HLA-C Alleles: Evaluates Class I alleles that play a key role in natural killer (NK) cell interaction and stem cell transplant outcomes.
• HLA-DRB1 Alleles: Detects the highly polymorphic Class II beta chain alleles, which are the most critical Class II markers for transplant matching and rheumatoid arthritis susceptibility.
• HLA-DQB1 Alleles: Identifies Class II alleles associated with Celiac Disease susceptibility and type 1 diabetes mellitus.
• HLA-DQA1 Alleles: Works in conjunction with DQB1 to form the functional HLA-DQ heterodimer receptor.
• HLA-DPB1 Alleles: Evaluates Class II alleles increasingly recognized as important in high-resolution matching for unrelated donor stem cell transplants.
• HLA-B*27 Allele: Specifically detects the presence of this marker, confirming susceptibility to Ankylosing Spondylitis, acute anterior uveitis, and reactive arthritis.
• HLA-B*57:01 Allele: Identifies patients at high risk for Abacavir hypersensitivity syndrome.
• HLA-B*15:02 Allele: Detects susceptibility to Carbamazepine-induced Stevens-Johnson Syndrome (SJS).
• HLA-B*58:01 Allele: Identifies genetic predisposition to severe cutaneous adverse reactions (SCAR) induced by Allopurinol.
• HLA-DQ2.5 and HLA-DQ8 Heterodimers: Specifically detects the genetic markers essential for ruling out Celiac Disease.
• HLA-DRB3, DRB4, and DRB5 Alleles: Evaluates secondary Class II loci that provide additional matching details for highly sensitized transplant candidates.
• Low-Resolution (Antigen-Level) Typing: Identifies the broad HLA antigen groups (e.g., HLA-A2, HLA-B27), suitable for solid organ screening.
• High-Resolution (Allele-Level) Typing: Identifies the specific nucleotide sequence and protein isoform (e.g., HLA-A*02:01, HLA-B*27:05), mandatory for bone marrow transplantation.
• Homozygosity vs. Heterozygosity: Determines whether the patient has inherited identical or different HLA alleles from each parent at each locus.
• MHC Class I Chain-Related Gene A (MICA): Some advanced panels detect MICA alleles, which can influence kidney transplant rejection.
• Null Alleles: Detects non-functional HLA genes that do not express proteins on the cell surface, preventing false-positive matching.
• Rare and Novel Alleles: Identifies uncommon genetic variants unique to specific ethnic populations in Pakistan.
• Haplotype Associations: Helps map inherited blocks of HLA genes, useful in family donor searches for bone marrow transplantation.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand that HLA Tissue Typing is often a time-sensitive investigation, particularly for patients awaiting urgent organ transplants or undergoing aggressive chemotherapy regimens. Because HLA typing is a highly complex molecular procedure involving DNA extraction, PCR amplification, and high-resolution sequencing or hybridization, the standard turnaround time (TAT) typically ranges from 5 to 10 working days. This timeframe ensures that every sample undergoes rigorous quality control, duplicate testing where necessary, and expert review by qualified molecular pathologists to guarantee absolute accuracy.

Chughtai Lab offers seamless and convenient options for patients to access their diagnostic reports. Once the report is finalized and signed off by our consultant pathologists, patients receive an automated SMS notification on their registered mobile number. Reports can be viewed, downloaded, and printed directly from the official Chughtai Lab website by entering the patient’s lab number and password. Additionally, patients can access their complete diagnostic history, including the HLA Tissue Typing report, via the Chughtai Lab Mobile App, available on both iOS and Android platforms. For patients requiring physical copies, reports can be collected from any of our conveniently located collection centers across Pakistan, or delivered directly to their doorstep through our home delivery service.

HLA Tissue Typing Class I & Class II (Patient) Findings Overview

The following table provides an overview of the parameters evaluated during HLA Tissue Typing Class I & Class II (Patient) and their clinical interpretations:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal / Clinically Significant Findings
HLA-A Locus (Class I)	Normal expression of two HLA-A alleles (one maternal, one paternal).	Specific alleles identified; mismatch with potential donor increases transplant rejection risk.
HLA-B Locus (Class I)	Normal expression of two HLA-B alleles.	Presence of disease-associated alleles (e.g., HLA-B27, HLA-B*57:01, HLA-B*15:02).
HLA-C Locus (Class I)	Normal expression of two HLA-C alleles.	Mismatches in stem cell transplantation associated with increased risk of graft failure.
HLA-DRB1 Locus (Class II)	Normal expression of two HLA-DRB1 alleles.	Presence of alleles associated with Rheumatoid Arthritis (shared epitope) or Multiple Sclerosis.
HLA-DQB1 Locus (Class II)	Normal expression of two HLA-DQB1 alleles.	Presence of HLA-DQB1*02 or *03:02, indicating high susceptibility to Celiac Disease.
HLA-DPB1 Locus (Class II)	Normal expression of two HLA-DPB1 alleles.	Non-permissive mismatches in HSCT, significantly increasing the risk of GVHD.
HLA-B*27 Status	Negative (Absent).	Positive (Present); strongly associated with Ankylosing Spondylitis and reactive arthritis.
HLA-B*57:01 Status	Negative (Absent).	Positive (Present); absolute contraindication for the use of Abacavir due to hypersensitivity risk.
HLA-DQ2 / HLA-DQ8 Status	Negative (Absent).	Positive (Present); confirms genetic susceptibility to gluten-sensitive enteropathy (Celiac Disease).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for HLA Tissue Typing Class I & Class II (Patient)?

• Experienced Healthcare Professionals: Our molecular pathology department is led by highly qualified consultant pathologists and molecular biologists with extensive experience in immunogenetics and transplant diagnostics.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate care throughout the testing process.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, participating in external quality assurance programs to ensure the highest accuracy.
• Professional Reporting: Our reports are comprehensive, detailed, and structured to provide clear, actionable information for transplant teams and clinicians.
• Modern Diagnostic Approach: We utilize state-of-the-art molecular platforms, including advanced PCR and sequencing technologies, to deliver high-resolution HLA typing.
• Comfortable Environment: All Chughtai Lab centers are designed to provide a clean, safe, and welcoming environment for patients and their families.
• Convenient Location: With a vast network of laboratories and collection centers across Pakistan, accessing our services is convenient and accessible.
• Commitment to Accurate Diagnosis: We are dedicated to providing precise diagnostic insights that form the foundation of successful medical treatments and transplant outcomes.